BofA lowered the firm’s price target on BeiGene to $152.50 from $180 and keeps a Neutral rating on the shares. Given updated sales data and the increasing competition of BTK inhibitors in China, the firm has “slightly” lowered its revenue forecast for 2024/25/26, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGNE: